Could SIRPA expression predict response to anti-PD-1 immunotherapy?
- PMID: 36332626
- DOI: 10.1016/j.ccell.2022.10.003
Could SIRPA expression predict response to anti-PD-1 immunotherapy?
Abstract
Immune checkpoint inhibitors (ICIs) offer significant promise for patients with melanoma; however, many patients succumb to de novo or acquired ICI resistance. In this issue of Cancer Cell, Zhou et al. propose a mechanism for signal-regulatory protein α1 (SIRPα) expression and describe how its loss may contribute to immunotherapy resistance.
Copyright © 2022 Elsevier Inc. All rights reserved.
Comment on
-
Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma.Cancer Cell. 2022 Nov 14;40(11):1324-1340.e8. doi: 10.1016/j.ccell.2022.10.012. Epub 2022 Nov 3. Cancer Cell. 2022. PMID: 36332624 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
